Background: Intravenous thrombolysis with recombinant tissue plasminogen activator (rt-PA) reduces disability in patients with ischemic stroke. However, its implementation in Chilean public general hospitals has been slow and faces some difficulties. Aim: To analyze the results of an intravenous thrombolysis protocol implementation in a public general hospital. Material and Methods: During a lapse of 28 months a standardized protocol for intravenous thrombolysis implemented in the emergency room of a public hospital, was prospectively evaluated. Fifty four patients with ischemic stroke were treated and assessed three months later as outpatients. Results: At three months of follow-up, 66.4% of patients subjected to thrombolysis had ...
Intravenous (IV) thrombolysis with recombinant tissue plasminogen activator (rt-PA) is the only avai...
Objective: Stroke is a serious cause of mortality and disability. The caregiver of the patients may ...
Intravenous (IV) thrombolysis with recombinant tissue plasminogen activator (rt-PA) is the only avai...
Background: Intravenous thrombolysis with recombinant tissue plasminogen activator (rt-PA) reduces ...
© 2016, Sociedad Medica de Santiago. All Rights Reserved. Background: Intravenous thrombolysis with ...
Background: The only accepted treatment for acute ischemic stroke is thrombolysis with recombinant ...
Background: The only accepted treatment for acute ischemic stroke is thrombolysis with recombinant ...
Background: The only accepted treatment for acute ischemic stroke is thrombolysis with recombinant t...
Acute stroke is the second leading cause of death after heart diseases in the world. Acute ischemic ...
Acute stroke is the second leading cause of death after heart diseases in the world. Acute ischemic ...
Acute stroke is the second leading cause of death after heart diseases in the world. Acute ischemic ...
Acute stroke is the second leading cause of death after heart diseases in the world. Acute ischemic ...
Acute stroke is the second leading cause of death after heart diseases in the world. Acute ischemic ...
Objective: Stroke is a serious cause of mortality and disability. The caregiver of the patients may ...
BACKGROUND AND AIMS: Thrombolytic therapy with intravenous recombinant tissue plasminogen activat...
Intravenous (IV) thrombolysis with recombinant tissue plasminogen activator (rt-PA) is the only avai...
Objective: Stroke is a serious cause of mortality and disability. The caregiver of the patients may ...
Intravenous (IV) thrombolysis with recombinant tissue plasminogen activator (rt-PA) is the only avai...
Background: Intravenous thrombolysis with recombinant tissue plasminogen activator (rt-PA) reduces ...
© 2016, Sociedad Medica de Santiago. All Rights Reserved. Background: Intravenous thrombolysis with ...
Background: The only accepted treatment for acute ischemic stroke is thrombolysis with recombinant ...
Background: The only accepted treatment for acute ischemic stroke is thrombolysis with recombinant ...
Background: The only accepted treatment for acute ischemic stroke is thrombolysis with recombinant t...
Acute stroke is the second leading cause of death after heart diseases in the world. Acute ischemic ...
Acute stroke is the second leading cause of death after heart diseases in the world. Acute ischemic ...
Acute stroke is the second leading cause of death after heart diseases in the world. Acute ischemic ...
Acute stroke is the second leading cause of death after heart diseases in the world. Acute ischemic ...
Acute stroke is the second leading cause of death after heart diseases in the world. Acute ischemic ...
Objective: Stroke is a serious cause of mortality and disability. The caregiver of the patients may ...
BACKGROUND AND AIMS: Thrombolytic therapy with intravenous recombinant tissue plasminogen activat...
Intravenous (IV) thrombolysis with recombinant tissue plasminogen activator (rt-PA) is the only avai...
Objective: Stroke is a serious cause of mortality and disability. The caregiver of the patients may ...
Intravenous (IV) thrombolysis with recombinant tissue plasminogen activator (rt-PA) is the only avai...